Effect of immunomodulating medications in complex regional pain syndrome: A systematic review

Clinical Journal of Pain

Volumn 28, Issue 4, 2012, Pages 355-363

  Dirckx, Maaike ^a   Stronks, Dirk L ^a   Groeneweg, George ^a   Huygen, Frank J P M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

complex regional pain syndrome (CRPS); efficacy; immunomodulating medication

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CORTICOTROPIN; CORTISONE; DEXAMETHASONE; FC RECEPTOR; GLUCOCORTICOID; HYDROCORTISONE; IBANDRONIC ACID; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; PAMIDRONIC ACID; PIROXICAM; PLACEBO; PREDNISOLONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL (TOPIC); COMPLEX REGIONAL PAIN SYNDROME; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE DURATION; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EDEMA; FLU LIKE SYNDROME; HEADACHE; HUMAN; INFLAMMATION; MEDLINE; OSTEOCLAST ACTIVITY; OUTCOME ASSESSMENT; PAIN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE; STELLATE GANGLION BLOCK; STUDY DESIGN; SYSTEMATIC REVIEW;

CAUSALGIA; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; PUBMED;

EID: 84859627977     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e31822efe30     Document Type: Review

References (69)

1. Veldman PH, Reynen HM, Arntz IE, et al. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet. 1993;342:1012-1016. (Pubitemid 23314802)
2. Stanton-Hicks M, Jänig W, Hassenbusch S, et al. Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain. 1995;63:127-133.
3. Harden RN, Bruehl S, Perez RS, et al. Validation of proposed criteria (the "Budapest Criteria") for complex regional pain syndrome. Pain. 2010;150:268-274.
4. Jänig W, Baron R. Complex regional pain syndrome: mystery explained? Lancet Neurol. 2003;2:687-697. (Pubitemid 37311322)
5. de Mos M, de Bruijn AG, Huygen FJ, et al. The incidence of complex regional pain syndrome: a population-based study. Pain. 2007;129:12-20. (Pubitemid 46551364)
6. de Mos M, Sturkenboom MC, Huygen FJ. Current understandings on complex regional pain syndrome. Pain Pract. 2009;9:86-99.
7. Oyen WJ, Arntz IE, Claessens RM, et al. Reflex sympathetic dystrophy of the hand: an excessive inflammatory response? Pain. 1993;55:151-157. (Pubitemid 23323163)
8. Birklein F, Schmelz M, Schifter S, et al. The important role of neuropeptides in complex regional pain syndrome. Neurology. 2001;57:2179-2184. (Pubitemid 34016448)
9. Huygen FJ, de Bruijn AG, de Bruin MT, et al. Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm. 2002;11:47-51. (Pubitemid 34252547)
10. Wesseldijk F, Huygen FJ, Heijmans-Antonissen C, et al. Tumor necrosis factor-alpha and interleukine-6 are not correlated with the characteristics of Complex Regional Pain Syndrome type 1 in 66 patients. Eur J Pain. 2008;12: 716-721. (Pubitemid 351778250)
11. Wesseldijk F, Huygen FJ, Heijmans-Antonissen C, et al. Six years follow-up of the levels of TNF-alpha and IL-6 in patients with complex regional pain syndrome type 1. Mediators Inflamm. 2008;2008:469439.
12. Groeneweg JG, Huygen FJ, Heijmans-Antonissen C, et al. Increased endothelin-1 and diminished nitric oxide levels in blister fluids with intermediate cold type complex regional pain syndrome type 1. BMC Musculoskelet Disord. 2006; 7:91.
13. Heijmans-Antonissen C, Wesseldijk F, Munnikes RJ, et al. Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1. Mediators Inflamm. 2006;2006: 28398.
14. Alexander GM, van Rijn MA, van Hilten JJ, et al. Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain. 2005;116:213-219. (Pubitemid 40957124)
15. Uçeyler N, Eberle T, Rolke R, et al. Differential expression patterns of cytokines in complex regional pain syndrome. Pain. 2007;132:195-205. (Pubitemid 47494574)
16. Maihöfner C, Handwerker HO, Neundörfer B, et al. Mechanical hyperalgesia in complex regional pain syndrome: a role for TNF-alpha? Neurology. 2005;65:311-313. (Pubitemid 41022383)
17. Bernateck M, Karst M, Gratz KF, et al. The first scintigraphic detection of tumor necrosis factor-alpha in patients with complex regional pain syndrome type 1. Anesth Analg. 2010; 110:211-215.
18. Huygen FJ, Niehof S, Zijlstra FJ, et al. Successful treatment of CRPS 1 with anti-TNF. J Pain Symptom Manage. 2004;27: 101-103.
19. Goebel A, Stock M, Deacon R, et al. Intravenous immunoglobulin response and evidence for pathogenic antibodies in a case of complex regional pain syndrome 1. Ann Neurol. 2005; 57:463-464. (Pubitemid 40343974)
20. Huygen FJ, de Bruin AG, Klein J, et al. Neuroimmune alterations in the complex regional pain syndrome. Eur J Pharmacol. 2001;429:101-113. (Pubitemid 33043986)
21. Perez RS, Zuurmond WW, Bezemer PD, et al. The treatment of complex regional pain syndrome type I with free radical scavengers: a randomized controlled study. Pain. 2003; 102:297-307. (Pubitemid 36369309)
22. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids- new mechanisms for old drugs. N Engl J Med. 2005; 353:1711-1723.
23. Choo-Kang BS, Hutchison S, Nickdel MB, et al. TNF-blocking therapies: an alternative mode of action? Trends Immunol. 2005;26:518-522. (Pubitemid 41297681)
24. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173: 699-703.
25. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91: 4082-4085. (Pubitemid 24139577)
26. Barlogie B, Tricot G, Anaissie E. Thalidomide in the management of multiple myeloma. Semin Oncol. 2001;28: 577-582. (Pubitemid 33138158)
27. Corrado A, Santoro N, Cantatore FP. Extra-skeletal effects of bisphosphonates. Joint Bone Spine. 2007;74:32-38. (Pubitemid 46240986)
28. Negi VS, Elluru S, Sibéril S, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007;27:233-245. (Pubitemid 46790823)
29. Russek HI, Russek AS, Doerner AA, et al. Cortisone in treatment of shoulder-hand syndrome following acute myocardial infarction. AMA Arch Intern Med. 1953;91: 487-492.
30. Steinbrocker O, Neustadt D, Lapin L. Shoulder-hand syndrome, sympathetic block compared with corticotrophin and cortisone therapy. J Am Med Assoc. 1953;153:788-791.
31. Rosen PS, Graham W. The shoulder-hand syndrome: historical review with observations on seventy-three patients. Can Med Assoc J. 1957;77:86-91.
32. Glick EN. Reflex dystrophy (algoneurodystrophy): results of treatment by corticosteroids. Rheumatol Rehabil. 1973;12: 84-88.
33. Mowat AG. Treatment of the shoulder-hand syndrome with corticosteroids. Ann Rheum Dis. 1974;33:120-123.
34. Glick EN, Helal B. Post-traumatic neurodystrophy. Treatment by corticosteroids. Hand. 1976;8:45-47.
35. Kozin F, McCarty DJ, Sims J, et al. The reflex sympathetic dystrophy syndrome. I. Clinical and histologic studies: evidence for bilaterality, response to corticosteroids and articular involvement. Am J Med. 1976;60:321-331.
36. Kozin F, Ryan LM, Carerra GF, et al. The reflex sympathetic dystrophy syndrome (RSDS). III. Scintigraphic studies, further evidence for the therapeutic efficacy of systemic corticosteroids, and proposed diagnostic criteria. Am J Med. 1981;70: 23-30. (Pubitemid 11183512)
37. Christensen K, Jensen EM, Noer I. The reflex dystrophy syndrome response to treatment with systemic corticosteroids. Acta Chir Scand. 1982;148:653-655. (Pubitemid 13221465)
38. Poplawski ZJ, Wiley AM, Murray JF. Post-traumatic dystrophy of the extremities. J Bone Joint Surg Am. 1983;65: 642-655.
39. Dirksen R, Rutgers MJ, Coolen JM. Cervical epidural steroids in reflex sympathetic dystrophy. Anesthesiology. 1987;66: 71-73. (Pubitemid 17218031)
40. Tountas AA, Noguchi A. Treatment of posttraumatic reflex sympathetic dystrophy syndrome (RSDS) with intravenous blocks of a mixture of corticosteroid and lidocaine: a retrospective review of 17 consecutive cases. J Orthop Trauma. 1991;5:412-419.
41. Braus DF, Krauss JK, Strobel J. The shoulder-hand syndrome after stroke: a prospective clinical trial. Ann Neurol. 1994;36:728-733. (Pubitemid 24337631)
42. Grundberg AB. Reflex sympathetic dystrophy: treatment with long-acting intramuscular corticosteroids. J Hand Surg Am. 1996;21:667-670. (Pubitemid 26265108)
43. Zyluk A. Results of the treatment of posttraumatic reflex sympathetic dystrophy of the upper extremity with regional intravenous blocks of methylprednisolone and lidocaine. Acta Orthop Belg. 1998;64:452-456. (Pubitemid 29024258)
44. Okada M, Suzuki K, Hidaka T, et al. Complex regional pain syndrome type I induced by pacemaker implantation, with a good response to steroids and neurotropin. Intern Med. 2002;41:498-501. (Pubitemid 34727585)
45. Taskaynatan MA, Ozgul A, Tan AK, et al. Bier block with methylprednisolone and lidocaine in CRPS type 1: a randomized, double-blinded, placebo-controlled study. Reg Anesth Pain Med. 2004;29:408-412. (Pubitemid 39221885)
46. Kalita J, Vajpayee A, Misra UK. Comparison of prednisolone with piroxicam in complex regional pain syndrome following stroke: a randomized controlled trial. QJM. 2006;99: 89-95. (Pubitemid 43210749)
47. Bianchi C, Rossi S, Turi S, et al. Long-term functional outcome measures in corticosteroid-treated complex regional pain syndrome. Eura Medicophys. 2006;42:103-111. (Pubitemid 44048033)
48. Zyluk A, Puchalski P. Treatment of early complex regional pain syndrome type 1 by a combination of mannitol and dexamethasone. J Hand Surg Eur Vol. 2008;33:130-136. (Pubitemid 351638605)
49. Munts AG, van der Plas AA, Ferrari MD, et al. Efficacy and safety of a single intrathecal methylprednisolne bolus in chronic complex regional pain syndrome. Eur J Pain. 2010;14:523-528.
50. Bernateck M, Rolke R, Birklein F, et al. Successful intravenous regional block with low-dose tumor necrosis factor-α antibody infliximab for treatment of complex regional pain syndrome 1. Anesth Analg. 2007;105:1148-1151.
51. Rajkumar SV, Fonseca R, Witzig TE. Complete resolution of reflex sympathetic dystrophy with thalidomide treatment. Arch Intern Med. 2001;161:2502-2503. (Pubitemid 33043126)
52. Ching DW, McClintock A, Beswick F. Successful treatment with low-dose thalidomide in a patient with both Behçet's Disease and complex regional pain syndrome type 1: case report. J Clin Rheumatol. 2003;9:96-98. (Pubitemid 36531881)
53. Schwartzman RJ, Chevlen E, Bengtson K. Thalidomide has activity in treating complex regional pain syndrome. Arch Intern Med. 2003;163:1487-1488. (Pubitemid 36758923)
54. Maillefert JF, Chatard C, Owen S, et al. Treatment of refractory reflex sympathetic dystrophy with pamidronate. Ann Rheum Dis. 1995;54:687.
55. Cortet B, Flipo RM, Cocquerelle P, et al. Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of efficacy and safety of the second generation bisphosphonate pamidronate. Clin Rheumatol. 1997;16:51-56. (Pubitemid 27101292)
56. Adami S, Fossaluzza V, Gatti D, et al. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis. 1997;56:201-204. (Pubitemid 27144208)
57. Varenna M, Zucchi F, Ghiringhelli D, et al. Intravenous clonadrate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J Rheumatol. 2000;27:1477-1483. (Pubitemid 30354048)
58. Siminoski K, Fitzgerald AA, Flesch G, et al. Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding. J Bone Miner Res. 2000;15: 2052-2055.
59. Kubalek I, Fain O, Paries J, et al. Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases. Rheumatology(Oxford). 2001;40:1394-1397.
60. Robinson JN, Sandom J, Chapman PT. Efficacy of pamidronate in complex regional pain syndrome type 1. Pain Med. 2004;5:276-280. (Pubitemid 39369247)
61. Manicourt DH, Brasseur JP, Boutsen Y, et al. Role of alendronate in therapy for posttraumatic complex regional pain syndrome type 1 of the lower extremity. Arthritis Rheum. 2004;50:3690-3697. (Pubitemid 39488698)
62. Breuer B, Pappagallo M, Ongseng F, et al. An open-label pilot trial of ibandronate for complex regional pain syndrome. Clin J Pain. 2008;24:685-689.
63. Santamato A, Ranieri M, Panza F, et al. Role of biphosphonates and lymphatic drainage type Leduc in the complex regional pain syndrome (shoulder-hand syndrome). Pain Med. 2009;10:179-185.
64. Goebel A, Netal S, Schedel R, et al. Human pooled immunoglobulin in the treatment of chronic pain syndromes. Pain Med. 2002;3:119-127.
65. Goebel A, Baranowski A, Maurer K, et al. Intravenous immunoglobulin treatment of the complex regional pain syndrome. Ann Intern Med. 2010;152:152-158.
66. Bruehl S, Harden RN, Galer BS, et al. External validation of IASP diagnostic criteria for complex regional pain syndrome and proposed research diagnostic criteria. Pain. 1999;81:147-154. (Pubitemid 29199910)
67. Harden RN, Bruehl S, Stanton-Hicks M, et al. Proposed new diagnostic criteria for the complex regional pain syndrome. Pain Med. 2007;8:326-331. (Pubitemid 47039415)
68. Schwartzman R, Irving G, Wallace M, et al, A multicenter, open-label 12 week study with extension to evaluate the safety and efficacy of lenalidomide (cc-5013) in the treatment of type-1 complex regional pain syndrome. Poster Presentation 11th World Congress on Pain (Sydney), August 21-26, 2005.
69. Brunner F, Schmid A, Kissling R, et al. Biphosphonates for the therapy of complex regional pain syndrome I-Systematic review. Eur J Pain. 2009;13:17-21.